To further assess the dynamic immune response to RT + IT that may underlie the lack of Conc.IT efficacy, we performed timepoint flow cytometry analyses of tumor-infiltrating immune cells in the course of therapy response at day 6 (d6), day 12 (d12) and day 18 (d18) post-treatment initiation, in both the PDG-Ink4a and PDG-p53 models. The gene discussed is TP53; the disease is neoplasm.